2-[5-(4-chlorophenyl)-4-[3-[4-[4-[[4-[[(2R)-4-(4-hydroxypiperidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylamino]phenyl]piperazin-1-yl]phenyl]-2-methyl-1-propan-2-ylpyrrole-3-carbonyl]oxyethylphosphonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-[5-(4-chlorophenyl)-4-[3-[4-[4-[[4-[[(2R)-4-(4-hydroxypiperidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylamino]phenyl]piperazin-1-yl]phenyl]-2-methyl-1-propan-2-ylpyrrole-3-carbonyl]oxyethylphosphonic acid
• 化学式: C₅₅H₆₃ClF₃N₆O₁₀PS₃
• 分子量: 1187.7
• InChiKey: LZSLSLBZKFXOSJ-VZUYHUTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  79
• 可旋转键数：
  22
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  253
• 氢给体数：
  5
• 氢受体数：
  19

文献信息

• BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20140199234A1

  公开（公告）日：2014-07-17

  Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.

  抑制剂Bcl-2/Bcl-xL及含有该抑制剂的组合物已被披露。还披露了在治疗需要抑制Bcl-2/Bcl-xL以获益的疾病和状况中使用Bcl-2/Bcl-xL抑制剂的方法，如癌症。
• Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US11491168B2

  公开（公告）日：2022-11-08

  The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor alone or in combination with a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

  本公开提供了一种药物组合物，其包含 Bcl-2/Bcl-xL 抑制剂、化疗剂和药学上可接受的载体。本公开还提供了一种治疗癌症的方法，包括向有需要的受试者单独施用治疗有效量的Bcl-2/Bcl-xL抑制剂或与治疗有效量的化疗剂联合施用。本公开还提供了将 Bcl-2/Bcl-xL 抑制剂和化疗剂组合用于制造抗肿瘤药物的方法。在本公开中，Bcl-2/Bcl-xL 抑制剂与化疗药物联合使用可显著增强抗肿瘤效果。
• COMBINATION OF BCL-2/BCL-XL INHIBITORS AND CHEMOTHERAPEUTIC AGENT AND USE THEREOF
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US20200297743A1

  公开（公告）日：2020-09-24

  The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor alone or in combination with a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.
• US9096625B2
  申请人：——

  公开号：US9096625B2

  公开（公告）日：2015-08-04